Early predictors for developing allergic disease and asthma: examining separate steps in the 'allergic march'.
BACKGROUND
Sensitization and symptoms of allergic disease are strongly correlated, but little is known about the early clinical precursors of the development of allergen sensitization in childhood. The aim of this study was to identify these predictors, and to examine separately the effect of early sensitization on subsequent wheeze, asthma, rhinitis and eczema.


METHODS
In the Childhood Asthma Prevention Study, children with a family history of asthma were assessed for allergen sensitization, total serum IgE, wheeze, asthma, eczema and rhinitis at ages 18 months and 5 years. To examine predictors, at 18 months, for subsequent sensitization, children who were non-sensitized at 18 months and had data on sensitization at 5 years were investigated, n=375. To examine the predictors, at age 18 months, of subsequent onset of symptoms, children who did not have wheeze, asthma, eczema or rhinitis at 18 months were followed-up at 5 years, n=177.


RESULTS
Among children who were non-sensitized at age 18 months, the presence of eczema [adjusted relative risk (aRR), 1.67, 95% confidence interval (CI) 1.20-2.33], but not wheeze, asthma or rhinitis, was an independent predictor of the onset of sensitization by age 5 years. Among children who were asymptomatic at age 18 months, sensitization to any allergen at 18 months was an independent predictor for the presence of wheeze (aRR 2.41, 95% CI 1.28-4.55), asthma (aRR 4.66, 95% CI 1.88-11.54) and rhinitis (aRR 1.77, 95% CI 1.08-2.90), but not for the development of eczema (aRR 0.78, 95% CI 0.23-2.64) at 5 years.


CONCLUSIONS
In non-sensitized children, eczema, but not wheeze, asthma or rhinitis is a predictor for subsequent development of sensitization. This suggests that early childhood eczema, rather than wheeze and rhinitis, may promote subsequent allergen sensitization and raises the possibility that early management of eczema may reduce the prevalence of sensitization in children.
Almqvist
C
C
Woolcock Institute of Medical Research, Camperdown, NSW, Australia; University of Sydney, Sydney, NSW, Australia. catarina.almqvist@ki.se
Li
Q
Q
Britton
W J
WJ
Kemp
A S
AS
Xuan
W
W
Tovey
E R
ER
Marks
G B
GB
D000485:Allergens / Q000276:immunology*; D001249:Asthma / Q000175:diagnosis* / Q000276:immunology; D002675:Child, Preschool; D018450:Disease Progression; D004485:Eczema / Q000175:diagnosis* / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis*; D007073:Immunoglobulin E / Q000097:blood; D007223:Infant; D008297:Male; D011237:Predictive Value of Tests; D012135:Respiratory Sounds / Q000276:immunology; D012220:Rhinitis / Q000175:diagnosis* / Q000276:immunology; D012882:Skin Tests; D013147:Spirometry
D000485:Allergens; D007073:Immunoglobulin E